Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors

Gene Therapy

Volumn 13, Issue 24, 2006, Pages 1731-1736

  Yamamoto, S ^a   Deckter, L A ^a   Kasai, K ^a   Chiocca, E A ^a   Saeki, Y ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FIREFLY LUCIFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSDUCTION; HERPES SIMPLEX VIRUS 1; MOLECULAR IMAGING; MOUSE; NONHUMAN; ONCOLYTIC VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUBCUTANEOUS TISSUE TUMOR; TUMOR CELL DESTRUCTION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS GENE; VIRUS INFECTION; VIRUS REPLICATION; VIRUS VECTOR;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; GENETIC VECTORS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; LUCIFERASES; LUMINESCENT PROTEINS; MICE; MICE, NUDE; MODELS, ANIMAL; NEOPLASMS, EXPERIMENTAL; NEUROGLIA; ONCOLYTIC VIROTHERAPY; PHOSPHONOACETIC ACID; PROMOTER REGIONS (GENETICS); PURINES; VERO CELLS; VIRUS REPLICATION;

HUMAN HERPESVIRUS 1;

EID: 33845220588     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302831     Document Type: Article

References (27)

1. Phuangsab A, Lorence RM, Reichard KW, Peeples ME, Walter RJ. Newcastle disease virus therapy of human tumor xenografts: Antitumor effects of local or systemic administration. Cancer Lett 2001; 172: 27-36.
2. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 1998; 282: 1332-1334.
3. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821-825.
4. Chiocca EA. Oncolytic viruses. Nat Rev Cancer 2002; 2: 938-950.
5. Russell SJ. RNA viruses as virotherapy agents. Cancer Gene Ther 2002; 9: 961-966.
6. Zeh HJ, Bartlett DL. Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther 2002; 9: 1001-1012.
7. Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B et al. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 2001; 61: 2983-2995.
8. Peng KW, Facteau S, Wegman T, O'Kane D, Russell SJ. Noninvasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002; 8: 527-531.
9. Cook SH, Griffin DE. Luciferase imaging of a neurotropic viral infection in intact animals. J Virol 2003; 77: 5333-5338.
10. Luker GD, Bardill JP, Prior JL, Pica CM, Piwnica-Worms D, Leib DA. Noninvasive bioluminescence imaging of herpes simplex virus type 1 infection and therapy in living mice. J Virol 2002; 76: 12149-12161.
11. Le LP, Le HN, Dmitriev IP, Davydova JG, Gavrikova T, Yamamoto S et al. Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling. J Natl Cancer Inst 2006; 98: 203-214.
12. Knipe DM. The role of viral and cellular nuclear proteins in herpes simplex virus replication. Adv Virus Res 1989; 37: 85-123.
13. Roizman B, Whitley RJ. The nine ages of herpes simplex virus. Herpes 2001; 8: 23-27.
14. Roizman B. The function of herpes simplex virus genes: A primer for genetic engineering of novel vectors. Proc Natl Acad Sci USA 1996; 93: 11307-11312.
15. Rajcani J, Andrea V, Ingeborg R. Peculiarities of herpes simplex virus (HSV) transcription: An overview. Virus Genes 2004; 28: 293-310.
16. Contag PR, Olomu IN, Stevenson DK, Contag CH. Bioluminescent indicators in living mammals. Nat Med 1998; 4: 245-247.
17. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci USA 2002; 99: 377-382.
18. Contag CH, Bachmann MH. Advances in in vivo bioluminescence imaging of gene expression. Annu Rev Biomed Eng 2002; 4: 235-260.
19. Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene 2003; 22: 6865-6872.
20. Terada K, Wakimoto H, Tyminski E, Chiocca EA, Saeki Y. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models. Gene Therapy 2006; 13: 705-714.
21. Ichikawa T, Hogemann D, Saeki Y, Tyminski E, Terada K, Weissleder R et al. MRI of transgene expression: Correlation to therapeutic gene expression. Neoplasia 2002; 4: 523-530.
22. Schang LM, Rosenberg A, Schaffer PA. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J Virol 1999; 73: 2161-2172.
23. Schang LM, Rosenberg A, Schaffer PA. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J Virol 2000; 74: 2107-2120.
24. Purifoy DJ, Powell KL. Herpes simplex virus DNA polymerase as the site of phosphonoacetate sensitivity: Temperature-sensitive mutants. J Virol 1977; 24: 470-477.
25. Ejercito PM, Kieff ED, Roizman B. Characterization of herpes simplex virus strains differing in their effects on social behaviour of infected cells. J Gen Virol 1968; 2: 357-364.
26. Leopardi R, Roizman B. The herpes simplex virus major regulatory protein ICP4 blocks apoptosis induced by the virus or by hyperthermia. Proc Natl Acad Sci USA 1996; 93: 9583-9587.
27. Fu X, Meng F, Tao L, Jin A, Zhang X. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus. Gene Therapy 2003; 10: 1458-1464.